Parmax Pharma announces an open offer to acquire 26% stake at ₹36.50 per share, triggered by a change in control. The company reported a widened net loss of ₹4.16 crore for FY26, despite a 187% revenue jump.

Parmax Pharma Ltd. Open Offer

Parmax Pharma Ltd. has announced an open offer for a change in control, with acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah proposing to buy 23,46,250 equity shares, representing 26.00% of the expanded voting share capital, at an offer price of ₹36.50 per share. The offer period will run from July 30, 2026, to August 12, 2026.

Reader Takeaway: Open offer for control shift; widening losses despite revenue growth.

What just happened

An open offer for a change in control has been initiated for Parmax Pharma Ltd. by Dhiren Chandulal Shah and Sunil Chinubhai Shah. They are set to acquire 26.00% of the company's equity share capital at ₹36.50 per share. This follows a Share Purchase Agreement signed on June 13, 2026, with existing promoters.

Why this matters

This open offer signifies a potential shift in the company's management and strategic direction. For public shareholders, it presents an opportunity to exit their investment at a fixed price. However, the company's recent financial performance, marked by a significant increase in net loss, warrants careful consideration.

The backstory

Parmax Pharma Ltd. has reported a net loss of ₹4.16 crore for the financial year ended March 31, 2026. This is a substantial increase from the ₹0.20 crore loss in the previous fiscal year. While revenue surged by 187% to ₹6.00 crore in FY26 from ₹2.09 crore in FY25, the widening loss indicates that cost increases or operational inefficiencies outpaced revenue growth.

What changes now

The open offer, if fully subscribed, will lead to a change in the promoter group. The new management will likely implement their strategy, which could involve restructuring or new business initiatives. Shareholders need to decide whether to tender their shares during the offer period.

Risks to watch

The company's persistent loss-making status and the widening of net losses are significant concerns. Furthermore, the net worth has declined by 23% to ₹13.74 crore as of March 31, 2026, from ₹17.90 crore in the prior year, suggesting an erosion of shareholder equity.

Peer comparison

Information not available in the provided filing.

Context metrics (time-bound)

FY 2026 Financials (ended March 31, 2026):

• Revenue: ₹6.00 crore (up 187% from ₹2.09 crore in FY 2025)
• Loss after tax: (₹4.16 crore) (widened from (₹0.20 crore) in FY 2025)
• Net Worth: ₹13.74 crore (down 23% from ₹17.90 crore in FY 2025)
• EPS: (₹11.00)

Open Offer Details:

• Offer Size: 23,46,250 Equity Shares (26.00%)
• Offer Price: ₹36.50 per share
• Offer Open Date: July 30, 2026
• Offer Close Date: August 12, 2026